Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium
ECONOMY & POLICY

Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.

Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as "the future of cancer treatment". Rosatom and healthcare facilities are actively working in this field.

"Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science," said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.

The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation. Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as the future of cancer treatment. Rosatom and healthcare facilities are actively working in this field. Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science, said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC. The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code